Company's ability to build and maintain successful partnerships, patient recruitment expertise and its global reach cited as reasons for selection
CINCINNATI, Dec. 12 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced it was named "Best CRO" at the Scrip Awards held Dec. 4 in London. Kendle was selected from among leading global CROs by a distinguished panel of pharmaceutical industry executives. The annual awards competition, organized by Scrip World Pharmaceutical News, a leading provider of news and analysis for the global biopharmaceutical industry, is designed to recognize new standards of excellence and celebrate achievements that reflect cutting-edge science and the intellectually exciting and socially rewarding nature of the industry. This is the second year in a row Kendle has received the "Best CRO Award."
"Kendle is honored to be recognized once again by the Scrip expert panel as 'Best CRO'," noted Candace Kendle, PharmD, Chairman and Chief Executive Officer. "In a service business it's all about people, and at Kendle our associates offer exceptional qualities that make a real difference to our customers."
According to Scrip World Pharmaceutical News, "The judges felt that among Kendle's strengths are its ability to build and maintain successful partnerships, its global reach, patient recruitment expertise, its skills in core therapeutic areas as well as niche areas and its extensive pregnancy registry."
Selection criteria for the award included performance across multiple categories, including range of capabilities, exceeding sponsor expectations, ability to build solid long-term working relationships within biopharmaceutical companies, quality of data management and innovative strategies for regulatory guidance. In their deliberations, the judges looked at the range of services provided by the entrants, measures they have implemented to improve their performance or offer new services and the quality of their relationships with their customers.
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com.
|SOURCE Kendle International Inc.|
Copyright©2007 PR Newswire.
All rights reserved